Cell & Gene Therapies

© GettyImages/CiydemImages

Ncardia secures $60m to expand iPSC platform

By Jane Byrne

Ncardia, a human-induced pluripotent stem cell-based (iPSC) technology company, has secured more than US$60m in capital through a strategic partnership with Kiniciti, a US based investor with a focus on the global cell and gene therapy ecosystem.

© GettyImages/PonyWang

Sphere Fluidics closes $40m funding round

By Jane Byrne

Sphere Fluidics, a UK company that has developed and is commercializing single cell analysis systems underpinned by its picodroplet technology, has just closed a US$40m investment round.

Pic:getty/andrewbrookes

Resilience and Harvard University launch five year R&D alliance

By Rachel Arthur

The new alliance will focus on the development and manufacturing of complex medicines including biologics, vaccines, nucleic acids and cell and gene therapies; as well as looking to launch companies to advance the manufacture of such medicines.

© GettyImages/John M Lund Photography Inc

Marken to add Kenya and Ghana to GMP storage network

By Jane Byrne

Marken, the clinical trial logistics subsidiary of UPS Healthcare, is adding significant capacity to support increased demand for its clinical drug supply chain services, particularly for cell and gene clinical trials.

© GettyImages/Bet_Noire

Japan backs Takeda stem cell therapy targeting Crohn’s disease

By Jane Byrne

Takeda has received approval from Japan’s ministry of health to manufacture and market its stem cell therapy, Alofisel, for the treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn’s disease (CD).

© GettyImages/AlexanderFord

Ocular gene therapy biotech launches with $19M seed funding

By Jane Byrne

This month sees the launch of a new gene therapy player, Opus Genetics, a company backed and spun out by leading patient group Foundation Fighting Blindness’ venture arm, the Retinal Degeneration Fund (RD Fund).

© GettyImages/Zarina Lukash

Special Edition: Reviewing the advanced therapy pipeline

Santen looks to ways to reduce hurdles for patients in accessing advanced therapies

By Jane Byrne

As a relatively new player in the field of cell therapy, Santen Pharmaceutical has outlined how it is looking to collaborate with key stakeholders in order to shape relevant policies, forge meaningful partnerships and create an optimal environment for...